Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Reserpine
Drug ID BADD_D01926
Description An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
Indications and Usage Foe the treatment of hypertension
Marketing Status Discontinued
ATC Code C02AA02
DrugBank ID DB00206
KEGG ID D00197
MeSH ID D012110
PubChem ID 5770
TTD Drug ID D0J4JM
NDC Product Code 49452-6217; 71052-422; 17359-1000
Synonyms Reserpine | Rausedil | Rausedyl | Serpasil | Raunervil | V-Serp | V Serp | Raupasil | Serpivite
Chemical Information
Molecular Formula C33H40N2O9
CAS Registry Number 50-55-5
SMILES COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)O C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
FlushingPro-neuropeptide YP01303T516712890260; 3179619; 3351195; 1713314; 8462463
FlushingAdenylate cyclase type 1Q08828T636096322519; 6322205; 2167035; 6099681; 6323336; 3005188; 6317593; 6096801; 1629569; 2559045
FlushingSodium/potassium-transporting ATPase subunit alpha-1P05023T408006322519; 6322205; 2167035; 6099681; 6323336; 3005188; 6317593; 6096801; 1629569; 2559045
Metabolic disorderCarboxypeptidase EP16870T465468361347; 8306430; 8228984; 1436476; 1334187; 1376456; 8310814; 8189248; 8500992; 8743747; 1907749
Metabolic disorderSecretogranin-2P20616Not Available8361347; 8306430; 8228984; 1436476; 1334187; 1376456; 8310814; 8189248; 8500992; 8743747; 1907749
Metabolic disorderSynaptophysinP07825Not Available8361347; 8306430; 8228984; 1436476; 1334187; 1376456; 8310814; 8189248; 8500992; 8743747; 1907749
Metabolic disorderPeptidyl-glycine alpha-amidating monooxygenaseP19021Not Available8361347; 8306430; 8228984; 1436476; 1334187; 1376456; 8310814; 8189248; 8500992; 8743747; 1907749
Metabolic disorderSecretogranin-1P05060Not Available8361347; 8306430; 8228984; 1436476; 1334187; 1376456; 8310814; 8189248; 8500992; 8743747; 1907749
Systemic lupus erythematosusN-alpha-acetyltransferase 20P61599Not AvailableNot Available
UlcerSodium/potassium-transporting ATPase subunit alpha-1P05023T408006322519; 6322205; 2167035; 6099681; 6323336; 3005188; 6317593; 6096801; 1629569; 2559045
UlcerPro-neuropeptide YP01303T516712890260; 3179619; 3351195; 1713314; 8462463
UlcerAdenylate cyclase type 1Q08828T636096322519; 6322205; 2167035; 6099681; 6323336; 3005188; 6317593; 6096801; 1629569; 2559045
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pruritus23.03.12.001--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Rash23.03.13.001--Not Available
Sedation17.02.04.005--Not Available
Shock24.06.02.002--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Tension19.06.02.005--Not Available
Uveitis10.02.01.023; 06.04.03.003--
Vascular purpura23.06.01.008; 01.01.04.007; 24.07.06.011--Not Available
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Conjunctival hyperaemia06.04.01.004--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Lactation disorder21.05.02.004; 18.06.02.003--
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
The 2th Page    First    Pre   2    Total 2 Pages